These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35049189)

  • 1. Efficacy and safety of gemcitabine-capecitabine combination therapy for pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials.
    Ouyang G; Wu Y; Liu Z; Lu W; Li S; Hao S; Pan G
    Medicine (Baltimore); 2021 Dec; 100(48):e27870. PubMed ID: 35049189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of gemcitabine plus capecitabine in the treatment of advanced or metastatic pancreatic cancer: a systematic review and meta-analysis.
    Xiao BY; Wang BC; Lin GH; Li PC
    Ann Palliat Med; 2020 Jul; 9(4):1631-1642. PubMed ID: 32576005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine-based combination therapy compared with gemcitabine alone for advanced pancreatic cancer: a meta-analysis of nine randomized controlled trials.
    Jin SF; Fan ZK; Pan L; Jin LM
    Hepatobiliary Pancreat Dis Int; 2017 Jun; 16(3):236-244. PubMed ID: 28603091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea.
    Lee HS; Chung MJ; Park JY; Bang S; Park SW; Kim HG; Noh MH; Lee SH; Kim YT; Kim HJ; Kim CD; Lee DK; Cho KB; Cho CM; Moon JH; Kim DU; Kang DH; Cheon YK; Choi HS; Kim TH; Kim JK; Moon J; Shin HJ; Song SY;
    Medicine (Baltimore); 2017 Jan; 96(1):e5702. PubMed ID: 28072706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis.
    Ouyang G; Liu Z; Huang S; Li Q; Xiong L; Miao X; Wen Y
    World J Surg Oncol; 2016 Feb; 14():59. PubMed ID: 26927942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
    Li Y; Sun J; Jiang Z; Zhang L; Liu G
    J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone.
    Chen H; He R; Shi X; Zhou M; Zhao C; Zhang H; Qin R
    BMC Cancer; 2018 Oct; 18(1):1034. PubMed ID: 30352573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.
    Li D; Chen C; Zhou Y; Chen R; Fan X; Bi Z; Li Z; Liu Y
    Medicine (Baltimore); 2015 Sep; 94(35):e1345. PubMed ID: 26334891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.
    Herrmann R; Bodoky G; Ruhstaller T; Glimelius B; Bajetta E; Schüller J; Saletti P; Bauer J; Figer A; Pestalozzi B; Köhne CH; Mingrone W; Stemmer SM; Tàmas K; Kornek GV; Koeberle D; Cina S; Bernhard J; Dietrich D; Scheithauer W; ;
    J Clin Oncol; 2007 Jun; 25(16):2212-7. PubMed ID: 17538165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone.
    Xie DR; Liang HL; Wang Y; Guo SS; Yang Q
    World J Gastroenterol; 2006 Nov; 12(43):6973-81. PubMed ID: 17109519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of gemcitabine combined with targeted agent therapy versus gemcitabine monotherapy in the management of advanced pancreatic cancer.
    Li Q; Yuan Z; Yan H; Wen Z; Zhang R; Cao B
    Clin Ther; 2014 Jul; 36(7):1054-63. PubMed ID: 24986485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials.
    Li Q; Yan H; Liu W; Zhen H; Yang Y; Cao B
    PLoS One; 2014; 9(8):e104346. PubMed ID: 25093849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma.
    de Jong EJM; Janssen QP; Simons TFA; Besselink MG; Bonsing BA; Bouwense SAW; Geurts SME; Homs MYV; de Meijer VE; Tjan-Heijnen VCG; van Laarhoven HWM; Valkenburg-van Iersel LBJ; Wilmink JW; van der Geest LG; Koerkamp BG; de Vos-Geelen J;
    Int J Cancer; 2022 May; 150(10):1654-1663. PubMed ID: 34935139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials.
    Ciliberto D; Botta C; Correale P; Rossi M; Caraglia M; Tassone P; Tagliaferri P
    Eur J Cancer; 2013 Feb; 49(3):593-603. PubMed ID: 22989511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: a meta-analysis.
    Tian W; Ding W; Kim S; Xu X; Pan M; Chen S
    Pancreatology; 2013; 13(4):415-22. PubMed ID: 23890141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of neoadjuvant treatment and surgery first for resectable or borderline resectable pancreatic carcinoma: A systematic review and network meta-analysis of randomized controlled trials.
    Huan L; Yu F; Cao D; Zhou H; Qin M; Cao Y
    PLoS One; 2024; 19(3):e0295983. PubMed ID: 38451955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis.
    Gresham GK; Wells GA; Gill S; Cameron C; Jonker DJ
    BMC Cancer; 2014 Jun; 14():471. PubMed ID: 24972449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The addition of S-1 to gemcitabine-based chemotherapy improves survival with increased toxicity for patients with advanced pancreatic cancer: combined meta-analysis of efficacy and safety profile.
    Liu Y; Huang QK; Hong WD; Wu JM; Sun XC
    Clin Res Hepatol Gastroenterol; 2015 Apr; 39(2):254-60. PubMed ID: 25304193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.
    Zhang XW; Ma YX; Sun Y; Cao YB; Li Q; Xu CA
    Target Oncol; 2017 Jun; 12(3):309-321. PubMed ID: 28353074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
    Petrioli R; Roviello G; Fiaschi AI; Laera L; Marrelli D; Roviello F; Francini E
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):683-90. PubMed ID: 25618415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.